uniQure N.V. (QURE) PT Raised to $19.00 at Leerink Swann
uniQure N.V. (NASDAQ:QURE) had its price target lifted by equities researchers at Leerink Swann from $17.00 to $19.00 in a report issued on Friday, MarketBeat.com reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Leerink Swann’s price target would suggest a potential downside of 1.40% from the stock’s current price.
Several other equities analysts also recently weighed in on QURE. ValuEngine raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research raised shares of uniQure N.V. from a “sell” rating to a “hold” rating and set a $9.25 target price on the stock in a research note on Wednesday, August 9th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $17.00 target price on shares of uniQure N.V. in a research note on Friday, June 30th. Finally, Chardan Capital set a $13.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $13.54.
uniQure N.V. (NASDAQ:QURE) traded up 27.11% during mid-day trading on Friday, hitting $19.27. 9,934,411 shares of the stock were exchanged. The stock’s 50 day moving average is $9.85 and its 200 day moving average is $7.25. The stock’s market cap is $492.54 million. uniQure N.V. has a 52-week low of $4.72 and a 52-week high of $19.34.
uniQure N.V. (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.05). The business had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $2.92 million. uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. Analysts forecast that uniQure N.V. will post ($3.06) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “uniQure N.V. (QURE) PT Raised to $19.00 at Leerink Swann” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/20/uniqure-n-v-qure-pt-raised-to-19-00-at-leerink-swann.html.
Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of uniQure N.V. by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 14,659 shares during the last quarter. Oxford Asset Management acquired a new stake in shares of uniQure N.V. during the first quarter valued at about $100,000. Mangrove Partners acquired a new stake in shares of uniQure N.V. during the second quarter valued at about $247,000. Weiss Multi Strategy Advisers LLC increased its position in shares of uniQure N.V. by 266.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after acquiring an additional 40,000 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of uniQure N.V. by 4.1% in the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares in the last quarter. Institutional investors and hedge funds own 29.86% of the company’s stock.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.